Abstract
Cyclin D1 plays a key role in the regulation of the G1/S transition through the cell cycle. Deregulation of cyclin D1, most often leading to overexpression of the gene, has been reported in many tumor types. It has been suggested that cyclin D1 overexpression could be an alternative mechanism for pRb inactivation. We have previously found Rb gene mutations in 55% of malignant thyroid tumors. In the present study, we examined the cyclin D1 gene expression and amplification in 24 tumor samples (two of them are benign goiters) randomly selected from the same series of thyroid tumors, to see whether cyclin D1 over-expression is present in those specimens without Rb gene mutations. We found a four- to fivefold increase in cyclin D1 expression in 7 of 22 thyroid carcinomas as compared with that in benign nodular goiters. Six of them were found in carcinomas without Rb gene mutations. Among the remaining 15 thyroid carcinoma samples, 11 were found previously to have Rb gene mutations. The association between increased cyclin D1 expression and absence of Rb mutation is statistically significant (p < 0.05). We found no evidence of the cyclin D1 gene amplification or rearrangement to account for such an increase in cyclin D1 expression. We conclude that cyclin D1 overexpression may be relevant to thyroid carcinogenesis. Two mechanisms may be involved in the inactivation of pRb: one is through Rb gene mutations, and the other is by cyclin D1 overexpression.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hartwell, L.H. and Kastan, M.B. (1994). Science 266, 1821–1828.
Hunter, T. and Pines, J. (1994). Cell 79, 573–582.
Norbury, C. and Nurse, P. (1992). Annu. Rev. Biochem. 61, 441–470.
Evans, T., Rosenthal, E. T., Youngblom, J., Distel, D., and Hunt, T. (1983). Cell 33, 389–396.
Hunter, T. and Pines, J. (1991). Cell 66, 1071–1074.
Rosenberg, C. L., Kim, H. G., Shows, T. B., Kronenberg, H. M., and Arnold, A. (1991). Oncogene 6, 449–453.
Rosenberg, C. L., Wong, E., Petty, E. M., Balf, A. E., Tsujimoto, Y., Harris, N. L., et al. (1991). Proc. Natl. Acad. Sci. USA 88, 9638–9642.
Motokura, T., Bloom, T., Kim, H. G., Juppner, H., Ruderman, J. M., Kronenberg, H. M., et al. (1991). Nature 350, 512–515.
Schauer, I. E., Siriwardana, S., Langan, T. A., and Sclafani, R. A. (1994). Proc. Natl. Acad. Sci. USA 91, 7827–7831.
Jiang, W., Zhang, Y.-J., Kahn, S. M., Hollstein, M. C., Santella, R. M., Lu, S.-H., et al. (1993). Proc. Natl. Acad. Sci. USA 90, 9026–9030.
Lammie, G. A., Fantl, V., Smith, R., Schuuring, E., Brookes, S., Michaelides, R., et al. (1991). Oncogene 6, 439–444.
Michalides, R., van Veelen, N., Hart, A., Loftus, B., Wientjens, E., and Balm, A. (1995). Cancer Res. 55, 975–978.
Jare, P., Fernandez, P. L., Campo, E., Nadal, A., Bosch, F., Aiza, G., et al. (1994). Cancer Res. 54, 4813–4817.
Hinds, P. W., Dowdy, S. F., Ng Eaton, E., Arnold, A., and Weinberg, R. A. (1994). Proc. Natl. Acad. Sci. USA 91, 709–713.
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnord, A., and Schmidt, E. V. (1994). Nature 369, 669–671.
Bodrug, S. E., Warner, B. J., Bath, M. L., Lindemans, G. J., Harris, A. W., and Adams, J. M. (1994). EMBO J. 13, 2124–2130.
Xiong, Y., Connolly, T., Futcher, B., and Beach, D. (1991). Cell 65, 691–699.
Hinds, P. W., Mittnacht, S., Dulic, V., Arnold, A., Reed, S. I., and Weinberg, R. A. (1992). Cell 70, 993–1006.
Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., and Weinberg, R. A. (1993). Cell 73, 499–511.
Zou, M. J., Shi, Y. and Farid, N. R. (1994). Endocrine 2, 193–198.
Farid, N. R., Shi, Y., and Zou, M. J. (1994). Endocr. Rev. 15, 202–232.
Kurzrock, R., Ku, S., and Talpaz, M. (1995). Cancer 75, 584–590.
Gillett, C., Fantl, V., Smith, R., Fisher, C., Bartek, J., Dickson, C., et al. (1994). Cancer Res. 54, 1812–1817.
Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., et al. (1993). Oncogene 8, 2127–2133.
Xu, X., Bayle, H., Olson, D., and Levine, A. J. (1993). Genes Dev. 71, 1126–1132
Muller, H., Lukas, J., Schneider, A., Warthoe, P., Bartek, J., Eilers, M., et al. (1994). Proc. Natl. Acad. Sci. USA 91, 2945–2949.
Filmus, J., Robles, A. I., Shi, W., Wong, M. J., Colombo, L. L., and Conti, C. J. (1994). Oncogene 9, 3627–3633.
Daksis, J. I., Lu, R. Y., Facchini, L. M., Marhin, W. W., and Penn, L. J. Z. (1994). Oncogene 9, 3635–3645.
Shi, Y., Zou, M. J., Schmidt, H., Juhasz, F., Stensky, V., Robb, D., et al. (1991). Cancer Res. 51, 2690–2693.
Shi, Y., Zou, M. J., and Farid, N. R. (1993). Clin. Endocrinol. 39, 269–274.
Hermanek, P. and Sobin, L. H. (1987). In: TNM Classification of Malignant Tumours. Springer-Verlag, Berlin, pp. 33–35.
Misrahi, M., Loosfelt, H., Atger, M., Sar, S., Guiochon-Mantel, A., and Milgrom, E. (1990). Biochem. Biophys. Res. Commun. 166, 394–403.
Shi, Y., Parhar, R. S., Zou, M. J., Al-Sedairy, S. T., and Farid, N. R. (1994). Br. J. Cancer 70, 440–444.
Zou, M. J., Shi, Y., Al-Sedairy, S., Hussain, S. S., and Farid, N. R. (1995). Cancer 76, 314–318.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zou, M., Shi, Y., Farid, N.R. et al. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocr 8, 61–64 (1998). https://doi.org/10.1385/ENDO:8:1:61
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:8:1:61